Treating psoriasis in the elderly: biologics and small molecules

Megna, Matteo; Potestio, Luca; Fabbrocini, Gabriella; Camela, Elisa

doi:10.1080/14712598.2022.2089020

Cited by 37 publications

(29 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, elderly patients represent an increasing proportion of patients with psoriasis. Biologics and small molecules seem to be a valuable option ( 60 ). In addition, anti-interleukin (IL)-23 therapies are assessed as safe and effective options for elderly patients ( 61 ).…”

Section: Discussionmentioning

confidence: 99%

Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses

et al. 2022

View full text Add to dashboard Cite

PurposeBased on a large number of systematic reviews and meta-analyses exploring the relationship between psoriasis and various health outcomes, we conducted an comprehensive analysis to assess the strength and evidence for the association between psoriasis and medical end-point ramifications in patients.MethodsWe searched related meta-analyses, investigating the links between psoriasis and medical ramifications from three databases. All summary effect sizes, 95% CIs, heterogeneity, and small-study effects in the included meta-analyses were recalculated. We assessed the methodological quality of included articles with the AMSTAR 2 tool and graded the epidemiological evidence. Subgroup analysis based on the severity of psoriasis and study design were also performed.ResultsA total of 38 articles comprising 85 unique meta-analyses were included in this study. Although 69 outcomes were statistically significant, only 8 outcomes (nonvascular dementia, ulcerative colitis, pediatric dyslipidemia, gestational diabetes, gestational hypertension, fracture, multiple sclerosis, and schizophrenia) showed a high quality of epidemiological evidence.ConclusionWe found that psoriasis increased the risk of 69 health outcomes, and 8 outcomes were graded as high-quality evidence. No evidence was found that psoriasis was beneficial for any medical end point. However, to verify our results, more large-sample, multi-center prospective cohort studies are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses

et al. 2022

View full text Add to dashboard Cite

show abstract

“…1 In these patients, psoriasis management is challenging. 2 Indeed, comorbidities, polypharmacy, drug interactions, and side effects are more frequent as well as conventional systemic treatments (methotrexate, cyclosporine, and acitretin) are often contraindicated and show a higher risk of adverse events or drug interactions. 2 We have read with great interest the article recently published by Ricardo et al 3 entitled "Where are the older adults?…”

mentioning

confidence: 99%

“…2 Indeed, comorbidities, polypharmacy, drug interactions, and side effects are more frequent as well as conventional systemic treatments (methotrexate, cyclosporine, and acitretin) are often contraindicated and show a higher risk of adverse events or drug interactions. 2 We have read with great interest the article recently published by Ricardo et al 3 entitled "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" presenting a sub-analysis of a systematic review assessing the ethnoracial composition of randomized clinical trials.…”

mentioning

confidence: 99%

“…3 Recently, we performed a thorough review of the literature examining the current data on the safety and efficacy of biologics and small molecules for the treatment of psoriasis in the elderly. 2 A total of 28 studies on the use of biologics and small molecules in elderly psoriatic patients were considered. 2 According to Ricardo et al, 3 elderly patients are often unconsidered in clinical trials, and population-specific data are required to make evidence-based therapeutic recommendations.…”

mentioning

confidence: 99%

“…2 A total of 28 studies on the use of biologics and small molecules in elderly psoriatic patients were considered. 2 According to Ricardo et al, 3 elderly patients are often unconsidered in clinical trials, and population-specific data are required to make evidence-based therapeutic recommendations.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Reply to “Where are the older adults? Age distribution of nail psoriasis‐randomized clinical trials' participants: a systematic review” by Ricardo JW et al.

et al. 2022

Self Cite

View full text Add to dashboard Cite

Obtaining formal safety and efficacy data in adequately samplesized clinical trials is therefore paramount.Limitations include the low proportion of studies reporting a number of older adult participants, restricting our search to MEDLINE, and the inclusion of published RCTs only.Obtaining population-specific data is required to make evidence-based therapeutic recommendations. Therefore, we advocate for the inclusion of representative populations of older adults in NP CTs.

show abstract

A comprehensive study on the application of machine learning in psoriasis diagnosis and treatment: taxonomy, challenges and recommendations

Ghorbian,

Ghobaei-Arani,

Ghorbian

2024

Artif Intell Rev

View full text Add to dashboard Cite

Treating psoriasis in the elderly: biologics and small molecules

Cited by 37 publications

References 59 publications

Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses

Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses

Reply to “Where are the older adults? Age distribution of nail psoriasis‐randomized clinical trials' participants: a systematic review” by Ricardo JW et al.

A comprehensive study on the application of machine learning in psoriasis diagnosis and treatment: taxonomy, challenges and recommendations

Contact Info

Product

Resources

About